Sort news by
02/25/2015 - 1:13pm

FDA's Orphan Drug Program is designed to encourage pharmaceutical companies to develop drugs for rare or 'orphan' diseases that might otherwise not be appealing to industry.

02/19/2015 - 5:00pm

February is American Heart Month, and MDF has partnered with Drs. Katharine Hagerman and Marianne Goodwin to highlight important research on cardiac issues in myotonic dystrophy for our readers

02/19/2015 - 11:02am

To support myotonic dystrophy drug development efforts, MDF held a science workshop in September 2014 at our annual conference. The workshop brought together more than 50 DM researchers and industry representatives from around the world to review where we are in the development of clinical trial endpoint measures for DM.

02/19/2015 - 10:26am

As part of MDF's countdown to the IDMC-10, we are introducing you to some of the international DM researchers who will attend the conference. Meet Dr. Bé Wieringa, MDF Lifetime Achievement awardee and leading investigator.

02/11/2015 - 5:36pm

As the sole DM-only patient advocacy organization in the US, MDF plays an important role in the search for treatments, in improving care, and ensuring that the DM community voice is heard as we move forward. To continue to meet our obligations to our community and to our mission of Care and a Cure, MDF held its annual strategic planning offsite last weekend.